Home World News HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus... World News HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 488 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR One in Five of Older Patients with EBC Treated in a... December 13, 2022 How People With Cancer Can Benefit From Online Therapy October 22, 2020 From smart knives to virtual reality tumours: five innovations in understanding... August 29, 2022 Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with... January 9, 2026 Load more HOT NEWS 3rd Grader Writes Note for Teacher Battling Breast Cancer to Read... A Peripheral Immune Signature of Responsiveness to PD-1 Blockade in cHL A Combination of Nivolumab Plus Ipilimumab Prolongs PFS versus Nivolumab Alone... Mammograms Can Detect COVID-19 Vaccination Swelling, Causing Cancer Scares
